Quarterly report · Q2
4578.TEDINET S100RHW0
Period2023-01-01 → 2023-06-30
Filed2023-07-31
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥947.5bn | 2023-01-01 → 2023-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥499.2bn | 2023-04-01 → 2023-06-30d | Cons. | Revenue IFRS |
| Revenue | ¥1.74T | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥814.3bn | 2022-01-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥434.0bn | 2022-04-01 → 2022-06-30d | Cons. | Revenue IFRS |
| Operating income | ¥130.7bn | 2023-01-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥53.9bn | 2023-04-01 → 2023-06-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥67.1bn | 2022-01-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥46.4bn | 2022-04-01 → 2022-06-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥138.8bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥59.6bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥173.0bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥92.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥61.8bn | 2022-04-01 → 2022-06-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥102.6bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥41.2bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥133.9bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥69.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥46.5bn | 2022-04-01 → 2022-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥105.1bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥42.4bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss IFRS |
| Net income | ¥71.5bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥47.3bn | 2022-04-01 → 2022-06-30d | Cons. | Profit loss IFRS |
| Total assets | ¥3.31T | at 2023-06-30 | Cons. | Assets IFRS |
| Total assets | ¥3.10T | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.10T | at 2022-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥840.3bn | at 2023-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥840.3bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.47T | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.26T | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.26T | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.05T | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥2.43T | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.23T | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.23T | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥498.7bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥471.6bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥456.8bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥410.7bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥113.5bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥211.8bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥118.8bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥54.3bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥81.6bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥56.0bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥46.8bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥95.5bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥48.2bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥189.06 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥75.85 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥246.8 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥128.61 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥85.74 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥189.06 | 2023-01-01 → 2023-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥75.85 | 2023-04-01 → 2023-06-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥246.78 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥128.57 | 2022-01-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥85.69 | 2022-04-01 → 2022-06-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 73.4% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.7% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.8% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 88
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-06-30 | ¥87.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-06-30 | ¥44.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-06-30 | ¥66.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-06-30 | ¥33.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥21.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥11.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-06-30 | ¥7.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-06-30 | ¥4.0bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-06-30 | −¥21.1bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥11.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-06-30 | −¥21.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥11.5bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-06-30 | −¥25.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥12.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥17.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥9.2bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥17.4bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥9.2bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥9m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥4m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥8.0bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥5.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥226.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥122.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥226.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥122.2bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥54m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥40m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥6.7bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥4.5bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥637.9bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥334.7bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥637.9bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥334.7bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥133.6bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥61.0bn |
| —segment total | revenue | 2023-01-01 → 2023-06-30 | ¥968.7bn |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥510.7bn |
| —segment total | revenue external | 2023-01-01 → 2023-06-30 | ¥947.5bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥499.2bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥21.1bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥11.5bn |
| —segment total | segment profit | 2023-01-01 → 2023-06-30 | ¥156.0bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥66.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-01-01 → 2022-06-30 | ¥82.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-06-30 | ¥43.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-01-01 → 2022-06-30 | ¥62.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥32.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥20.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥11.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-01-01 → 2022-06-30 | ¥7.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-06-30 | ¥3.8bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-06-30 | −¥20.1bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥11.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-06-30 | −¥20.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥11.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥22.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥11.1bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥16.7bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥9.0bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥16.7bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥9.0bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥5m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥2m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥1.8bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.0bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥205.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥115.4bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥205.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥115.4bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥11m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥7m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥28.1bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥16.9bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥529.3bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥277.2bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥529.3bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥277.2bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥52.2bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥34.9bn |
| —segment total | revenue | 2022-01-01 → 2022-06-30 | ¥834.4bn |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥445.3bn |
| —segment total | revenue external | 2022-01-01 → 2022-06-30 | ¥814.3bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥434.0bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-06-30 | ¥20.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥11.3bn |
| —segment total | segment profit | 2022-01-01 → 2022-06-30 | ¥90.0bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥57.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 894
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating profit loss IFRS | Prior1QuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 1985000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3821000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_ReportableSegmentsMember | 57537000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration_ReconcilingItemsMember | -11140000000 | JPY |
| Operating profit loss IFRS | Prior1QuarterDuration | 46396000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 334691000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 122195000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 9187000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 33118000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 499193000000 | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | CurrentQuarterDuration | 499193000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 40000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 4000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 11444000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 11489000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -11489000000 | JPY |
| Intersegment revenue IFRS | CurrentQuarterDuration | － | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 334691000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 122236000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 9191000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 44563000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 510682000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -11489000000 | JPY |
| Revenue IFRS | CurrentQuarterDuration | 499193000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 60965000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | -4531000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 5816000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4013000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_ReportableSegmentsMember | 66263000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration_ReconcilingItemsMember | -12352000000 | JPY |
| Operating profit loss IFRS | CurrentQuarterDuration | 53911000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-07-31 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第16期第２四半期（自 2023年４月１日 至 2023年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)大塚ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Otsuka Holdings Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長兼CEO 樋口 達夫 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区神田司町二丁目９番地（同所は登記上の所在地であり、実際の業務は下記の最寄りの連絡場所で行っております。） | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03－6717－1410 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)財務会計部長 新井 敏文 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区港南二丁目16番４号 品川グランドセントラルタワー12階 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03－6717－1410 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)財務会計部長 新井 敏文 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E21183 | |
| Fund code | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |